2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Metabolic Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1372 Clonal dynamics and extra-hematologic disease in a CHIP/ccus natural history study

Nicholas Chien-Juei Lee, MD, Fernanda Gutierrez-Rodrigues, PhD2, Tania R Machado, BSN, RN3, Jennifer Lotter, MS4, Ivana Darden, RN5, Katherine Roskom6, Marcus Chen7, Theo Heller8, Neal Stuart Young, MD9, Bhavisha A Patel, MD10, Emma Groarke, MD11
1 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
2 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
3 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
4 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
5 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
6 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
7 National Heart, Lung, and Blood Institute, Bethesda, United States
8 National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, United States
9 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
10 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
11 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States

Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) is defined as presence of a myeloid neoplasia (MN) related somatic variant detected at a variant allele frequency (VAF) ≥2%. CHIP has been associated with an increased risk of MN and extra-hematologic manifestations, such as cardiovascular, liver, and bone diseases. Prospective CH data in healthy individuals is limited, particularly as testing is driven by clinical indications, and extra-hematologic manifestations have not been prospectively rigorously investigated.

 

Methods: Patients with CHIP (n=21) or clonal cytopenia of undetermined significance (CCUS, n=14) were enrolled on a prospective observational study at NIH (NCT04102423). CCUS was defined having CHIP mutations and Hb <10g/dL, platelets <100x109/L, or neutrophil count <1.5x109/L. Exclusion criteria were prior chemotherapy or known hematologic disorder. We performed comprehensive cardiopulmonary, hepatic, and bone density evaluations and targeted somatic testing using peripheral blood collected at enrollment and annually thereafter. Driver mutations were defined based on baseline highest VAF and clonal trajectories were based on patterns of expansion or regression over time.

 

Results: Median age was 65 years (range: 44-84). At enrollment, CHIP and CCUS  patients had one (n=15/21 and n=7/14) or ≥2 mutations (n=6/21 and n=7/14), respectively. Driver mutations commonly involved DNMT3A (n=14, 40%; median VAF of 12%) and TET2 (n=9, 26%; median VAF of 39%). Median follow-up was 2.8 years (range:1 month to 5.7 years). At enrollment, driver DNMT3A-CH was stable over median 3.4 years (ΔVAF +2.0%) and co-occurred with JAK2 or TET2-CH in 2 patients. Driver TET2-CH were also stable over median 2.3 years (ΔVAF +0.1%) but more frequently co-occurred with other CH (SF3B1, n=2; DNMT3A, n=1; JAK2+SRSF2, n=1).

Five participants, 2 with CHIP and 3 with CCUS, evolved to MN at a median 2.1 years (up to 3 years) of follow-up: CMML (n=3), MDS (n=1), and AML (n=1). At enrollment, one patient had an IDH2 mutation that co-occurred with ASXL1/SRSF2 mutations, and four patients had high VAF (>35%) TET2 mutations that co-occurred with ASXL1 and/or splicing factors mutations (SF3B1, n=2; SRSF2/ZRSR2, n=2). Clonal trajectories associated with MN evolution differed among patients. In a patient that harbored a likely biallelic TET2 variant (VAF >50%), CMML evolution coincided with acquisition of multiple NRAS/KRAS mutations and a marked expansion of a CBL mutation (5% to 59% VAF in a year). In two other patients, CMML evolution did not associate with acquisition of novel mutations but patients harbored large TET2 and splicing factors clones present since enrollment. In the remaining 2 patients, MDS/AML progression coincided with expansion of splicing factors, TP53, and/or NRAS mutations detected by annual screening.

All 5 individuals who progressed on study had a high-risk Clonal Hematopoiesis Risk Score (CHRS) at enrollment. Of those who have not progressed, there is only one patient with high-risk CHRS who has a driver IDH2 mutation (follow-up: 14 months).  

We further evaluated whether CHIP/CCUS was associated with cardiopulmonary, hepatic, and bone alterations. Eleven of 23 evaluable patients (48%) had clinically significant coronary artery calcification (≥ 100 Agatston units), regardless of presence of TET2 mutations. Liver disease, defined as elevated liver stiffness ≥ 8 kPa, was negligible (3%, n=1). There was no evidence of increased osteoporosis risk; dual-energy X-ray absorptiometry (n=23) T- and Z-score were 0.8 (IQR 0.2 to 1.3) and 0.0 (IQR -0.8 to 0.5).

Conclusions: In this prospective CHIP/CCUS natural history study, which excluded those who received chemotherapy, longitudinal clonal dynamics differed according to the mutated gene: DNMT3A clones were largely stable and did not associate with MN, while in a subgroup of patients with high VAF TET2 mutations, co-occurrence of secondary mutations in splicing factors or RASp genes (KRAS/NRAS/CBL) led to MN, most commonly CMML. High-risk CHRS identified patients at enrollment who evolved on trial and may be an appropriate inclusion criteria for interventional studies. In our cohort, the incidence of liver disease and osteoporosis was low, but there was significant coronary artery disease that may support CAC screening and pharmacologic intervention in CHIP patients.

Nicholas Chien-Juei Lee, MD: No relevant conflicts of interest to declare.